Response to Lehrer and Rheinstein.
作者信息
Fedewa Stacey A, Ma Jiemin, Jemal Ahmedin
机构信息
Data Science, American Cancer Society, Atlanta, GA, USA.
出版信息
J Natl Cancer Inst. 2020 Oct 1;112(10):1069-1070. doi: 10.1093/jnci/djaa093.
Abstract
摘要
相似文献
1
Response to Lehrer and Rheinstein.对莱勒和莱茵斯坦的回应。
J Natl Cancer Inst. 2020 Oct 1;112(10):1069-1070. doi: 10.1093/jnci/djaa093.
2
Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.关于：美国预防服务工作组建议不进行筛查后5年的前列腺癌发病率
J Natl Cancer Inst. 2020 Oct 1;112(10):1067-1068. doi: 10.1093/jnci/djaa092.
3
Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.美国预防服务工作组（USPSTF）对前列腺特异性抗原筛查的D级推荐的长期后果。
Cancer. 2020 Feb 15;126(4):694-696. doi: 10.1002/cncr.32605. Epub 2019 Dec 3.
4
New US Preventive Service Task Force recommendations for prostate cancer screening: a needed update, but not enough.美国预防服务工作组关于前列腺癌筛查的新建议：虽有必要更新，但仍显不足。
Einstein (Sao Paulo). 2017 Jul-Sep;15(3):7-10. doi: 10.1590/S1679-45082017ED4151.
5
Guideline: USPSTF recommends against PSA screening except in men 55 to 69 years who express a preference for it.指南：美国预防服务工作组建议不进行前列腺特异性抗原（PSA）筛查，55至69岁表示愿意接受筛查的男性除外。
Ann Intern Med. 2018 Sep 18;169(6):JC28. doi: 10.7326/ACPJC-2018-169-6-028.
6
Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.回复：2012年美国预防服务工作组建议不鼓励基于前列腺特异性抗原的筛查后美国的全国前列腺癌筛查率
J Urol. 2016 Apr;195(4 Pt 1):928-9. doi: 10.1016/j.juro.2016.01.034. Epub 2016 Jan 21.
7
2008 US Preventive Services Task Force recommendations and prostate cancer screening rates.2008年美国预防服务工作组建议与前列腺癌筛查率
JAMA. 2012 Apr 25;307(16):1692-4. doi: 10.1001/jama.2012.534.
8
The current state of prostate-specific antigen testing.前列腺特异性抗原检测的现状
JAAPA. 2016 Sep;29(9):51-3. doi: 10.1097/01.JAA.0000490955.33308.6e.
9
A History of the United States Preventive Services Task Force: Its Expanding Authority and Need for Reform.美国预防服务工作组的历史：其不断扩大的权力及改革需求
J Urol. 2018 Jan;199(1):37-39. doi: 10.1016/j.juro.2017.08.078. Epub 2017 Aug 19.
10
Re: Turini et al.: The State of Prescreening Discussions About Prostate-specific Antigen Testing Following Implementation of the 2012 United States Preventive Services Task Force Statement (Urology 2017;104:122-130).回复：图里尼等人：2012年美国预防服务工作组声明实施后前列腺特异性抗原检测的预筛查讨论现状（《泌尿外科》2017年；104卷：122 - 130页）
Urology. 2018 Apr;114:246. doi: 10.1016/j.urology.2017.04.052. Epub 2017 May 26.
引用本文的文献
1
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics.《全国癌症状况年度报告》第 1 部分：国家癌症统计。
J Natl Cancer Inst. 2021 Nov 29;113(12):1648-1669. doi: 10.1093/jnci/djab131.
本文引用的文献
1
Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.关于：美国预防服务工作组建议不进行筛查后5年的前列腺癌发病率
J Natl Cancer Inst. 2020 Oct 1;112(10):1067-1068. doi: 10.1093/jnci/djaa092.
2
Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.美国预防服务工作组建议停止前列腺癌筛查 5 年后的发病率。
J Natl Cancer Inst. 2021 Jan 4;113(1):64-71. doi: 10.1093/jnci/djaa068.
3
Annual report to the nation on the status of cancer, part I: National cancer statistics.国家癌症报告：癌症现状年度报告第一部分：国家癌症统计数据。
Cancer. 2020 May 15;126(10):2225-2249. doi: 10.1002/cncr.32802. Epub 2020 Mar 12.
4
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.前列腺癌筛查：美国预防服务工作组推荐声明。
JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710.
5
Cancer incidence, survival and mortality: explaining the concepts.癌症发病率、生存率和死亡率：解释相关概念。
Int J Cancer. 2014 Oct 15;135(8):1774-82. doi: 10.1002/ijc.28990. Epub 2014 Jun 19.
Zotero 插件